Friday, October 9
Healthupdated today

Does the FDA approve Capricor's deramiocel for Duchenne cardiomyopathy?

Will the FDA approve Capricor Therapeutics' deramiocel Biologics License Application for Duchenne muscular dystrophy-associated cardiomyopathy by its November 22, 2026 PDUFA target action date?

40% yes — FDA approves deramiocel

Genuinely contested — a 9-3 negative advisory vote is a real headwind, but Capricor specifically refiled a narrower indication using new data the panel's own feedback called supportive, so this isn't simply a rerun of the vote that already happened

The bull case: the HOPE-3 data shows delayed disease progression, the committee's feedback on upper-limb function specifically was directionally supportive even as it voted against the broader cardiomyopathy claim, deramiocel would be first-in-class with no competing approved cell therapy for DMD cardiomyopathy, and a successful approval would be eligible for a Priority Review Voucher that adds standalone value. The bear case: a 9-3 advisory vote against effectiveness is one of the more lopsided negative panel votes in recent biotech history, FDA final decisions historically align with advisory panel votes more often than not, Piper Sandler's post-vote price target of $2 implies the sell-side sees the stock as pricing in a high chance of further rejection, and the panel's specific concerns centered on the statistical stability of the LVEF endpoint under different missing-data assumptions — a methodological critique that doesn't automatically go away just because the indication was narrowed.

Resolves Nov 22, 2026 · PDUFA target action date for deramiocel's BLA, extended from Aug 22 after Capricor submitted refined 24-month HOPE-3 upper-limb-function data as a major amendment

This is a resubmission with a rocky history: the FDA issued a Complete Response Letter on deramiocel in July 2025, lifted it in March 2026 as a Class 2 resubmission with an Aug 22, 2026 PDUFA date, then convened an advisory committee on July 29, 2026 that voted 9-3 that the evidence does not support effectiveness for the DMD-cardiomyopathy indication as proposed. CAPR shares cratered roughly 54% the next trading day (from $6.57 to $3.03) and Piper Sandler slashed its price target from $58 to $2. Capricor responded by submitting 24-month HOPE-3 open-label-extension data supporting a narrower, refined indication focused on upper-limb function — feedback the committee itself had called 'directionally supportive' even while voting against the broader cardiomyopathy claim — and the FDA accepted it as a major amendment, pushing the goal date to Nov 22, 2026. The stock has partially recovered to roughly $8.71 (Sept 27) on hopes the narrower refiling has a better shot. With 44 days left before the new goal date, no further company or FDA disclosures have surfaced since the extension was announced.

The FDA either approves the BLA (with or without labeling conditions) by the goal date, or it issues another Complete Response Letter or delays the decision further — a discrete regulatory action tied to a published target date.

Researched Oct 9, 2026 · tracked since Oct 9, 2026

Build a position

market 40%you 40%no edge

You agree with the market.

Nothing here has positive expected value — the price already reflects this view. Move the slider to where you think the odds actually are.

Take a side

FDA approves deramiocelthis is “yes”

The HOPE-3 open-label-extension data shows delayed disease progression, the advisory committee's own feedback on upper-limb function was directionally supportive even while voting against the broader cardiomyopathy claim, and deramiocel would be first-in-class with no competing approved cell therapy for DMD cardiomyopathy.

Long
CAPR Capricor TherapeuticsThe direct sponsor — deramiocel is effectively the company's whole value proposition, so approval or another rejection is a binary, company-defining catalyst.
Short
SRPT Sarepta TherapeuticsMaker of Elevidys, the only approved DMD gene therapy; a deramiocel rejection narrows the field of competing modalities for DMD cardiac care, while an approval introduces a validated new competitor.
Short
PTCT PTC TherapeuticsMarkets oral small-molecule DMD therapies; benefits at the margin from reduced competitive intensity in the DMD treatment landscape if deramiocel is rejected.
Short
SLDB Solid BiosciencesA small-cap pure-play DMD gene-therapy developer; higher-beta read-through on sentiment toward the DMD regulatory and funding landscape than the larger, diversified competitors.
Long
XBI SPDR S&P Biotech ETFBroad biotech-sentiment barometer; a first-in-class cell-therapy approval for a disease with no cardiac-specific cure today is a visible sector validation, while a second rejection feeds the opposite narrative about cell-therapy regulatory risk.
Short
BMRN BioMarin PharmaceuticalA diversified rare-disease biotech with its own neuromuscular-adjacent pipeline interests; a weak, diluted cross-read on sentiment toward rare-disease cell- and gene-therapy regulatory risk generally.
Long
ARKG ARK Genomic Revolution ETFConcentrated basket of cell- and gene-therapy innovators; a first-in-class cell-therapy approval for a cardiac indication validates the modality this fund is built around more directly than a broad biotech ETF would.

Worth knowing: A 9-3 negative advisory committee vote on effectiveness is a genuinely bad signal the FDA has historically weighted heavily — approval here would be swimming against a real headwind, not a formality, even with the refiled narrower indication.

FDA delays or rejects deramiocel again

A 9-3 advisory vote against effectiveness is one of the more lopsided negative panel votes in recent biotech history, FDA final decisions historically align with advisory panel votes more often than not, and the panel's core statistical concerns about the LVEF endpoint don't automatically resolve just because the indication was narrowed.

Short
CAPR Capricor TherapeuticsThe direct sponsor — deramiocel is effectively the company's whole value proposition, so approval or another rejection is a binary, company-defining catalyst.
Long
SRPT Sarepta TherapeuticsMaker of Elevidys, the only approved DMD gene therapy; a deramiocel rejection narrows the field of competing modalities for DMD cardiac care, while an approval introduces a validated new competitor.
Long
PTCT PTC TherapeuticsMarkets oral small-molecule DMD therapies; benefits at the margin from reduced competitive intensity in the DMD treatment landscape if deramiocel is rejected.
Long
SLDB Solid BiosciencesA small-cap pure-play DMD gene-therapy developer; higher-beta read-through on sentiment toward the DMD regulatory and funding landscape than the larger, diversified competitors.
Short
XBI SPDR S&P Biotech ETFBroad biotech-sentiment barometer; a first-in-class cell-therapy approval for a disease with no cardiac-specific cure today is a visible sector validation, while a second rejection feeds the opposite narrative about cell-therapy regulatory risk.
Long
BMRN BioMarin PharmaceuticalA diversified rare-disease biotech with its own neuromuscular-adjacent pipeline interests; a weak, diluted cross-read on sentiment toward rare-disease cell- and gene-therapy regulatory risk generally.
Short
ARKG ARK Genomic Revolution ETFConcentrated basket of cell- and gene-therapy innovators; a first-in-class cell-therapy approval for a cardiac indication validates the modality this fund is built around more directly than a broad biotech ETF would.

Worth knowing: Capricor specifically refiled using new 24-month HOPE-3 data addressing a narrower indication the panel's own feedback called supportive — treating a second rejection as a foregone conclusion ignores that this isn't a straight rerun of the vote that already happened.

6 sources, leaning both ways